BioSpace News Archive

Citius Pharmaceuticals, Inc. reported topline results from the pivotal Phase 3 trial of I/ONTAK, an engineered IL-2-diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma.

Matinas BioPharma announced today that Jerry Jabbour, Chief Executive Officer, has been invited to present at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022, at 3:00 p.m. ET.

Tonix Pharmaceuticals Holding Corp. today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to support a Phase 2 clinical trial with TNX-102 SL1 as a potential treatment for a subset of patients with Long COVID Syndrome (Long COVID) whose symptoms overlap with fibromyalgia.

SELLAS Life Sciences Group, Inc. today announced that an Investigational New Drug (“IND”) application to initiate the first clinical trial in China for 3D189, also known as SELLAS’ galinpepimut-S (GPS), has been approved by China’s National Medical Products Administration.

CareDx, Inc. today announced it will host the symposium, “Improved Precision with a Multimodality Approach,” during the annual American Society of Transplantation Cutting Edge of Transplantation.

The Multiple Sclerosis Society of Canada announced a nearly $1.35 million investment from Biogen Canada Inc., Hoffmann-La Roche Limited, and Brain Canada Foundation towards a new sub-cohort of the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis that follows pediatric-onset MS participants from the Canadian Pediatric Demyelinating Disease Study as they become adults to understand MS across the age-span.

According to a new study conducted by GSK, people age 50 or older in the US who have had COVID-19 may be at greater risk of developing shingles – a painful rash – compared to those who haven’t been diagnosed with COVID-19.

Two Chemical Series Identified to Facilitate Lead Optimisation Activities.

The industry analysis report is considered a valuable source of information about the global Kidney Stone Retrieval Devices industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

Peregrine Ventures, a leading investment firm dedicated to supporting life changing healthcare opportunities, today realized the USD 500 million exit from CartiHeal (USD 350 million down payment plus an additional USD 150 million milestone).